Raphaël Itzykson

15.3k total citations · 1 hit paper
139 papers, 6.7k citations indexed

About

Raphaël Itzykson is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Raphaël Itzykson has authored 139 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 120 papers in Hematology, 63 papers in Genetics and 45 papers in Molecular Biology. Recurrent topics in Raphaël Itzykson's work include Acute Myeloid Leukemia Research (111 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (41 papers) and Chronic Lymphocytic Leukemia Research (28 papers). Raphaël Itzykson is often cited by papers focused on Acute Myeloid Leukemia Research (111 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (41 papers) and Chronic Lymphocytic Leukemia Research (28 papers). Raphaël Itzykson collaborates with scholars based in France, United States and Italy. Raphaël Itzykson's co-authors include Andrea L. Richardson, Sridhar Ramaswamy, Inna Gitelman, Pierre Savagner, Sendurai A. Mani, Jing Yang, Christophé Côme, Joana Liu Donaher, Robert A. Weinberg and Pierre Fenaux and has published in prestigious journals such as Cell, The Lancet and Nature Communications.

In The Last Decade

Raphaël Itzykson

126 papers receiving 6.6k citations

Hit Papers

Twist, a Master Regulator of Morphogenesis, Plays an Esse... 2004 2026 2011 2018 2004 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis
    2004 3.1k citations Raphaël Itzykson et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Raphaël Itzykson France 31 3.5k 2.9k 2.0k 1.5k 1.2k 139 6.7k
Michael Heuser Germany 41 3.6k 1.0× 4.2k 1.4× 1.0k 0.5× 1.5k 1.0× 1.2k 1.0× 250 6.7k
Thoas Fioretos Sweden 39 2.5k 0.7× 2.5k 0.8× 981 0.5× 1.1k 0.7× 983 0.8× 153 5.6k
Marı́a José Calasanz Spain 43 3.0k 0.8× 2.2k 0.8× 866 0.4× 1.1k 0.7× 1.1k 0.9× 153 5.1k
Philippe Martiat Belgium 38 2.0k 0.6× 1.6k 0.5× 1.3k 0.7× 1.4k 0.9× 1.5k 1.3× 110 5.6k
Norma C. Gutiérrez Spain 41 3.3k 0.9× 3.4k 1.2× 1.7k 0.9× 1.2k 0.8× 683 0.6× 179 5.6k
Josef Vormoor Germany 35 3.2k 0.9× 2.7k 0.9× 3.5k 1.7× 938 0.6× 1.2k 1.1× 117 7.8k
Jacqueline Boultwood United Kingdom 46 5.2k 1.5× 3.6k 1.2× 808 0.4× 1.7k 1.1× 2.4k 2.0× 174 8.1k
Pieter A. van der Velden Netherlands 36 1.8k 0.5× 2.9k 1.0× 1.7k 0.8× 826 0.5× 867 0.7× 84 6.9k
Juan C. Cigudosa Spain 43 3.4k 1.0× 1.3k 0.5× 1.5k 0.8× 1.0k 0.7× 1.2k 1.1× 149 6.0k
George S. Vassiliou United Kingdom 36 5.1k 1.4× 4.2k 1.5× 1.1k 0.5× 4.4k 2.9× 1.1k 0.9× 108 8.4k

Countries citing papers authored by Raphaël Itzykson

Since Specialization
Citations

This map shows the geographic impact of Raphaël Itzykson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raphaël Itzykson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raphaël Itzykson more than expected).

Fields of papers citing papers by Raphaël Itzykson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raphaël Itzykson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raphaël Itzykson. The network helps show where Raphaël Itzykson may publish in the future.

Co-authorship network of co-authors of Raphaël Itzykson

This figure shows the co-authorship network connecting the top 25 collaborators of Raphaël Itzykson. A scholar is included among the top collaborators of Raphaël Itzykson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raphaël Itzykson. Raphaël Itzykson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhao, Lin‐Pierre, Emmanuelle Clappier, Matthieu Duchmann, et al.. (2025). Prognostic significance of monocytic-like phenotype in patients with AML treated with venetoclax and azacytidine. Blood Advances. 9(14). 3556–3565.
2.
Duchmann, Matthieu, et al.. (2024). Single-cell sequencing applications in acute myeloid leukemia. Leukemia & lymphoma. 66(2). 175–189.
3.
Onida, Francesco, Nico Gagelmann, Yves Chalandon, et al.. (2024). Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee. Blood. 143(22). 2227–2244. 8 indexed citations
4.
Hirsch, Pierre, Jérôme Lambert, Maxime Bucci, et al.. (2024). Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study. Blood Cancer Journal. 14(1). 97–97. 3 indexed citations
5.
Hunter, Anthony M., Mrinal M. Patnaik, Raphaël Itzykson, et al.. (2024). Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm. Blood. 144(19). 1987–1992. 4 indexed citations
6.
Lengliné, Étienne, Florence Rabian, Marco Cerrano, et al.. (2024). Blinatumomab consolidation for adult B-cell acute lymphoblastic leukemia in first and second complete remission. Blood Advances. 8(10). 2405–2409. 2 indexed citations
7.
Duployez, Nicolas, Juliette Lambert, Maël Heiblig, et al.. (2023). Hyperleukocytosis Increases the Risk of Early Relapses Independently of Genetics in AML. Blood. 142(Supplement 1). 4322–4322.
8.
Pronier, Elodie, Dorothée Selimoglu‐Buet, Raphaël Itzykson, et al.. (2022). Macrophage migration inhibitory factor is overproduced through EGR1 in TET2low resting monocytes. Communications Biology. 5(1). 110–110. 15 indexed citations
9.
Zhao, Lin‐Pierre, Emmanuelle Clappier, Marie Sébert, et al.. (2021). Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease. Leukemia. 35(9). 2720–2724. 25 indexed citations
10.
Raffoux, Emmanuel, Marie Robin, David Michonneau, et al.. (2021). Correction to: Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality. Leukemia. 35(3). 934–934. 6 indexed citations
11.
Beauvais, David, Isabelle Berthaut, Aurélie Cabannes‐Hamy, et al.. (2021). Semen Cryopreservation in Adolescents and Young Adults with Hematologic Diseases: from Bed to Benchside. Journal of Adolescent and Young Adult Oncology. 11(4). 389–393. 1 indexed citations
12.
Raffoux, Emmanuel, Marie Robin, David Michonneau, et al.. (2020). Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality. Leukemia. 35(1). 225–228. 7 indexed citations
13.
Lin, Kevin, Justine C. Rutter, Abigail Xie, et al.. (2020). Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer. Nature Genetics. 52(4). 408–417. 39 indexed citations
14.
Robin, Marie & Raphaël Itzykson. (2019). Contemporary treatment approaches to CMML – Is allogeneic HCT the only cure?. Best Practice & Research Clinical Haematology. 33(2). 101138–101138. 1 indexed citations
15.
Itzykson, Raphaël, Pierre Fenaux, Argiris Symeonidis, et al.. (2017). Prognostic Value of Early Drop in Platelets in Lower-Risk MDS. A Sub-Study from the European Leukemianet Lower-Risk MDS (EUMDS) Registry. Leukemia Research. 55. S10–S11. 1 indexed citations
16.
Dombret, Hervé & Raphaël Itzykson. (2017). How and when to decide between epigenetic therapy and chemotherapy in patients with AML. Hematology. 2017(1). 45–53. 25 indexed citations
17.
Itzykson, Raphaël, et al.. (2015). New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide. Experimental Hematology. 43(8). 661–672. 6 indexed citations
18.
19.
Itzykson, Raphaël, Olivier Kosmider, Thomas Cluzeau, et al.. (2011). Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 25(7). 1147–1152. 353 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael Heuser Breakdown of academic impact, for papers by Thoas Fioretos Breakdown of academic impact, for papers by Marı́a José Calasanz Breakdown of academic impact, for papers by Philippe Martiat Breakdown of academic impact, for papers by Norma C. Gutiérrez Breakdown of academic impact, for papers by Josef Vormoor Breakdown of academic impact, for papers by Jacqueline Boultwood Breakdown of academic impact, for papers by Pieter A. van der Velden Breakdown of academic impact, for papers by Juan C. Cigudosa Breakdown of academic impact, for papers by George S. Vassiliou
Rankless by CCL
2026